Sanofi recently announced that it has completed the acquisition of Protein Sciences, a vaccines biotechnology company based in Meriden, Connecticut in the United States. This completion follows Federal Trade Commission approval, having met all the conditions required for the closing of the transaction. The acquisition helped Sanofi Pasteur add Flublok, a promising product to its influenza vaccine portfolio.
Paris/France — Through the acquisition, Sanofi Pasteur, the vaccines global business unit of Sanofi, adds a promising product to its influenza vaccine portfolio: Flublok (Influenza Vaccine), the only recombinant protein-based influenza vaccine approved by the US Food and Drug Administration (FDA). In October 2016, Protein Sciences received approval from the FDA for the quadrivalent version of Flublok vaccine (Flublok Quadrivalent vaccine), indicated for adults 18 years and older.
“We are thrilled to welcome the talented employees and assets of Protein Sciences within Sanofi Pasteur,” said David Loew, Sanofi Executive Vice President and head of Sanofi Pasteur. “The addition of Flublok Quadrivalent vaccine represents a very attractive opportunity to complement our influenza vaccines portfolio.”
The acquisition of Protein Sciences fits with Sanofi Pasteur’s strategic initiative to explore non-egg-based influenza vaccine manufacturing technologies. “This acquisition is consistent with our strategic ambition of expanding our presence in the respiratory vaccine market, and builds on the recently announced collaboration on an investigational respiratory syncytial virus (RSV) monoclonal antibody,” added David Loew.